62Curated trials
Enterprise Evidence Report · NR-REPORT-V2.0
Bulgaria
Neuroscience Intelligence
Bulgaria neuroscience evidence report: current clinical, research, institution and source-linked intelligence.
Evidence rank #43 of 50 · Data maturity A · Research score 28.1 · Data confidence 100.0 / 100 · Snapshot 2026-10-29 06:18 UTC.
12Recruiting trials
4Publications
15Institutions
Executive interpretation
Bulgaria ranks #43 in the current NeuroRisk evidence-ranked market layer. This ranking summarizes indexed clinical, publication and institution evidence; it is not a probability of commercial success and not an investment recommendation.
Methodology status
Methodology NR-REPORT-V2.0. Clinical metrics and NCT evidence use only records classified as in_scope or related; out_of_scope records remain preserved outside these analytical counts. No synthetic ML confidence is presented as scientific probability. Counts and source links below are tied to the generation snapshot.
Methodology →Leading sponsors
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.40 recruiting
Boehringer Ingelheim30 recruiting
Hoffmann-La Roche30 recruiting
UCB Pharma30 recruiting
H. Lundbeck A/S30 recruiting
Sanofi22 recruiting
Novo Nordisk A/S20 recruiting
Celgene20 recruiting
ACADIA Pharmaceuticals Inc.20 recruiting
Otsuka Pharmaceutical Development & Commercialization, Inc.20 recruiting
Disease activity
Epilepsy15trials
Multiple Sclerosis9trials
Parkinsons8trials
Alzheimers6trials
Schizophrenia4trials
Depression4trials
Neurodevelopmental Other2trials
Bipolar Disorder2trials
Neuromuscular2trials
Other Psychiatry2trials
Research institutions
Institute of NeurobiologyOpenAlexlinked institution
Institute of Molecular BiologyOpenAlexlinked institution
Stephan Angeloff Institute of MicrobiologyOpenAlexlinked institution
Bulgarian Academy of SciencesOpenAlexlinked institution
Alexandrovska HospitalOpenAlexlinked institution
University Hospital St. Ivan RilskiOpenAlexlinked institution
National Heart HospitalOpenAlexlinked institution
New Bulgarian UniversityOpenAlexlinked institution
Military Medical AcademyOpenAlexlinked institution
Medical University PlovdivOpenAlexlinked institution
Clinical evidence trail
NCT07067463A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisRECRUITING
NCT07011732A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)RECRUITING
NCT06887192A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease PsychosisRECRUITING
NCT06798896RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresRECRUITING
NCT06701903Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety DisorderRECRUITING
NCT06463587Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)RECRUITING
NCT06290128A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) for Which the Usual Treatments do Not WorkACTIVE_NOT_RECRUITING
NCT05980949Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)RECRUITING
NCT05667142A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresRECRUITING
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)ACTIVE_NOT_RECRUITING
NCT04879628Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisACTIVE_NOT_RECRUITING
NCT04752774A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.RECRUITING
Research evidence trail
PUBMEDA simple method for identifying latent spasticity following compressive spinal cord injury by provoking clonic contractions of the hindpaw- and back musculature in rats.2026-10-01
PUBMEDClinical heterogeneity and diagnostic challenges in CASK-related neurodevelopmental disorders: a longitudinal observational study.2026-01-01
PUBMEDVariant Ataxia-Telangiectasia Presenting as Tremor-Dystonia Syndrome in a Bulgarian Religious Minority.2025-05-27
World Bank context
Macro indicators are shown only where a timestamped World Bank source row exists. Latest collection in this report: 2026-10-24 04:18 UTC. They are context, not NeuroRisk predictions.
Sources and provenance
ClinicalTrials.gov provides NCT evidence. PubMed/NCBI and OpenAlex provide research metadata. OpenAlex links institutions. World Bank indicators are included only when an explicit source row and year exist. NeuroRisk transformations add normalization, ranking and graph connections.
Limitations
Indexed corpus counts are not guaranteed exhaustive global totals. Scores are comparative decision-support signals. This report is not medical advice, regulatory advice, patent clearance, an investment recommendation or a guarantee of outcome.